Compare Medpace Holdings Inc (MEDP) vs Wolfspeed Inc (WOLF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs Wolfspeed Inc — how do they compare? Medpace Holdings Inc trades at $602 (market cap $16.82B), while Wolfspeed Inc trades at $31.61 (market cap $1.64B). The key difference: Medpace Holdings Inc is far larger — about 10.3× Wolfspeed Inc's market cap, and Medpace Holdings Inc is trading nearer its 52-week high, Wolfspeed Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Medpace Holdings Inc for 14 Days and Wolfspeed Inc for 19 Days on average.
| MEDP | WOLF | |
|---|---|---|
Market Cap | $16.82B | $1.64B |
Volume | 223,093 | 22,772,687 |
Sector | Health | Technology |
52-Week High | $630.19 | $73.68 |
52-Week Low | $393.42 | $14.80 |
Typical Hold Time | 14 Days | 19 Days |
Enterprise Value | $16.44B | $2.35B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $604.25, up 0.22% today, with a neutral technical signal and strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results expected on October 21, 2026. Revenue grew to $2.53 billion in 2025, with a net income margin of 17.67% and robust ROE of 162.15%. Analyst consensus is a $620.44 price target, though institutional sentiment is mixed with recent CEO share sales.
Outlook remains positive given earnings momentum and projected 2026 revenue growth to $2.8 billion. Key risks include high valuation multiples and insider selling. The stock offers upside to consensus target but requires monitoring of Q3 earnings and competitive pressures in medical services.
Wolfspeed (WOLF) trades at $31.37, down 1.45% on the day, with a bullish technical signal from moving averages. The company reported a net loss of $1.61 billion in 2025, but forecasts a return to profitability in 2026 with a net income of $4 million. Recent news highlights the expansion of its 200mm silicon carbide portfolio, positioning it for growth in AI and electrification markets.
The outlook is mixed; analyst consensus is a buy with a $54.32 price target, but significant risks include negative margins, high debt, and ongoing legal investigations. Revenue growth in power devices offers upside, yet achieving breakeven remains critical for sustained shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About Wolfspeed Inc
Wolfspeed is the global leader in wide bandgap semiconductors, specializing in silicon carbide (SiC) and gallium nitride (GaN) materials and devices. It operates a vertically integrated model, controlling the entire process from raw material substrate production to advanced power modules, serving as a critical infrastructure provider for electric vehicles (EVs), renewable energy, and AI data centers.
Read more on WOLF →
